2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 294

Serum Urate Levels Predict Joint Space Narrowing in Non-Gout Patients with Medial Knee Osteoarthritis
Abstract Number: 2158

Serum Uric Acid Is Positively Associated with Pulmonary Function in Korean Health Screening Examinees: A Cross-Sectional Study
Abstract Number: 205

Serum Uric Acid Lowering Treatment Appears Unnecessary during Hemodialysis
Abstract Number: 1225

Serum Uric Acid Testing Practices over Five Years Among Incident Gout Cases
Abstract Number: 1332

Severe Complications and Immunosuppressive Treatments in 33 Patients with Relapsing Polychondritis
Abstract Number: 827

Severe Gastrointestinal Disease in Early Systemic Sclerosis Is Associated with an Increased Risk of Mortality
Abstract Number: 2408

Severe Juvenile Arthritis Associated with a De Novo Gain-of-Function Germline Mutation in MYD88
Abstract Number: 1975

Severity and Improvement of Morning Stiffness Independently Associate with Tenosynovitis in Patients with Rheumatoid Arthritis
Abstract Number: 986

Sex-Specific Associations Between Improvement in Gait Mechanics and Improvement in Pain, Function, and Abductor Strength after Total Hip Arthroplasty
Abstract Number: 485

Sexual Dimorphism of Popliteal Lymph Node Collapse As a Biomarker of Disease Progression in the Tumor Necrosis Factor Transgenic Mouse Model of Rheumatoid Arthritis
Abstract Number: 466

Sexually Dimorphic Dysbiosis of Gut Microbiota in Tumor Necrosis Factor Transgenic Mice with Inflammatory-Erosive Arthritis
Abstract Number: 2157

Share the Fate: Fibroblast-like Synoviocyte Cell-to-Cell Organelle Transfer Is Directed By the Inflammatory Microenvironment
Abstract Number: 1559

Shared Genetic Predisposition in Rheumatoid Arthritis–Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis: A Genetic Association Study
Abstract Number: 2477

Short Term Clinical Response to Initial Treatment with High Versus Low Dose Methotrexate in Mono- and Combination Therapy in Early Rheumatoid Arthritis Patients
Abstract Number: 980

Short-Course Glucocorticoids in ANCA-Associated Vasculitis: A Proof of Concept Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].